| Dr Jenna Carpenter, DO | |
|
2525 Us Highway 431, Pulmonary And Sleep Associates, Suite 210, Boaz, AL 35957-5934 | |
| (256) 840-4653 | |
| (256) 840-3182 |
| Full Name | Dr Jenna Carpenter |
|---|---|
| Gender | Female |
| Speciality | Pulmonary Disease |
| Experience | 10 Years |
| Location | 2525 Us Highway 431, Boaz, Alabama |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144427006 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Marshall Medical Centers | Boaz, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Marshall Medical Center South Manganaris Pulmonology | 5092976787 | 6 |
News Archive
SXC Health Solutions Corp., a leading provider of pharmacy benefits management (PBM) services and Health Care Information Technology (HCIT) solutions to the healthcare benefits management industry, announced today that its board of directors has declared a nominal dividend on the issued and outstanding common shares of the Company to effect a two-for-one stock split.
Targets, time and money pressures create a lethal cocktail that could allow superbugs to thrive in our ambulances said UNISON, the UK's largest health union, this week.
The American Diabetes Association (ADA), members of the Congressional Diabetes Caucus and diabetes experts, will host a congressional briefing, Wednesday, January 23 at 1 p.m. in 2218 Rayburn House Office Building to discuss the annual diabetes cost estimates for 2007, which were compiled in a study by the Lewin Group on behalf of the ADA.
SATAI (www.satai.us) and the South Texas Regional Center of Innovation and Commercialization (www.strcic.com) today announced an investment of $1.045 million in Azaya Therapeutics, Inc. through the Texas Emerging Technology Fund (ETF) for the commercialization of Azaya's proprietary Protein Stabilized Nanoparticle (PSN) technology platform to produce targeted, safer and more effective formulations of chemotherapy pharmaceuticals for the treatment of cancer.
As part of a multinational, collaborative effort, researchers from the University of North Carolina School of Medicine and scores of other institutions from all over the world have helped identify over 100 locations in the human genome associated with the risk of developing schizophrenia, in what is the largest genomic study published on any psychiatric disorder to date.
› Verified 5 days ago
| Entity Name | Marshall Medical Center South Manganaris Pulmonology |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013299304 PECOS PAC ID: 5092976787 Enrollment ID: O20120405000090 |
News Archive
SXC Health Solutions Corp., a leading provider of pharmacy benefits management (PBM) services and Health Care Information Technology (HCIT) solutions to the healthcare benefits management industry, announced today that its board of directors has declared a nominal dividend on the issued and outstanding common shares of the Company to effect a two-for-one stock split.
Targets, time and money pressures create a lethal cocktail that could allow superbugs to thrive in our ambulances said UNISON, the UK's largest health union, this week.
The American Diabetes Association (ADA), members of the Congressional Diabetes Caucus and diabetes experts, will host a congressional briefing, Wednesday, January 23 at 1 p.m. in 2218 Rayburn House Office Building to discuss the annual diabetes cost estimates for 2007, which were compiled in a study by the Lewin Group on behalf of the ADA.
SATAI (www.satai.us) and the South Texas Regional Center of Innovation and Commercialization (www.strcic.com) today announced an investment of $1.045 million in Azaya Therapeutics, Inc. through the Texas Emerging Technology Fund (ETF) for the commercialization of Azaya's proprietary Protein Stabilized Nanoparticle (PSN) technology platform to produce targeted, safer and more effective formulations of chemotherapy pharmaceuticals for the treatment of cancer.
As part of a multinational, collaborative effort, researchers from the University of North Carolina School of Medicine and scores of other institutions from all over the world have helped identify over 100 locations in the human genome associated with the risk of developing schizophrenia, in what is the largest genomic study published on any psychiatric disorder to date.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jenna Carpenter, DO 2525 Us Highway 431, Pulmonary And Sleep Associates, Suite 210, Boaz, AL 35957-5934 Ph: (256) 840-4653 | Dr Jenna Carpenter, DO 2525 Us Highway 431, Pulmonary And Sleep Associates, Suite 210, Boaz, AL 35957-5934 Ph: (256) 840-4653 |
News Archive
SXC Health Solutions Corp., a leading provider of pharmacy benefits management (PBM) services and Health Care Information Technology (HCIT) solutions to the healthcare benefits management industry, announced today that its board of directors has declared a nominal dividend on the issued and outstanding common shares of the Company to effect a two-for-one stock split.
Targets, time and money pressures create a lethal cocktail that could allow superbugs to thrive in our ambulances said UNISON, the UK's largest health union, this week.
The American Diabetes Association (ADA), members of the Congressional Diabetes Caucus and diabetes experts, will host a congressional briefing, Wednesday, January 23 at 1 p.m. in 2218 Rayburn House Office Building to discuss the annual diabetes cost estimates for 2007, which were compiled in a study by the Lewin Group on behalf of the ADA.
SATAI (www.satai.us) and the South Texas Regional Center of Innovation and Commercialization (www.strcic.com) today announced an investment of $1.045 million in Azaya Therapeutics, Inc. through the Texas Emerging Technology Fund (ETF) for the commercialization of Azaya's proprietary Protein Stabilized Nanoparticle (PSN) technology platform to produce targeted, safer and more effective formulations of chemotherapy pharmaceuticals for the treatment of cancer.
As part of a multinational, collaborative effort, researchers from the University of North Carolina School of Medicine and scores of other institutions from all over the world have helped identify over 100 locations in the human genome associated with the risk of developing schizophrenia, in what is the largest genomic study published on any psychiatric disorder to date.
› Verified 5 days ago
Jacqueline Valadez, DO Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 2692 Us Highway 431, Boaz, AL 35957 Phone: 256-558-6000 | |
Dr. Andrew Grout Finlay Jr., MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 2505 Us Highway 431, Boaz, AL 35957 Phone: 256-593-8114 | |
Alvin V Tenchavez, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2986 Us Highway 431, Boaz, AL 35957 Phone: 256-840-8181 Fax: 256-744-7272 | |
Maria Gloria Rabin-go, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 603 Medical Center Pkwy, Boaz, AL 35957 Phone: 256-558-6000 Fax: 800-541-9612 | |
Dr. George Philip, MD. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2525 Us Highway 431, Suite 250, Boaz, AL 35957 Phone: 256-539-4080 Fax: 256-539-4099 | |
Dr. Rommel C Go, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 603b Medical Center Pkwy, Boaz, AL 35957 Phone: 256-558-6000 Fax: 256-558-6000 |